RDY Stock News & Catalysts – Dr. Reddy's Laboratories

FEATURED

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY

NEW YORK, Sept. 24, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Dr. Reddy's Laboratories Limited ("Dr. Reddy's" or the "Company") (NYSE:RDY). Such

Summary

Sep 24, 2026, 6:38 PM ·PRNewswire

RECENT

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy’s Laboratories Limited - RDY

NEW YORK, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Dr. Reddy’s Laboratories Limited ("Dr. Reddy’s" or the "Company") (NYSE:RDY). Such

Sep 22, 2026, 8:54 PM ·Globe Newswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY

NEW YORK, Sept. 17, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Dr. Reddy's Laboratories Limited ("Dr. Reddy's" or the "Company") (NYSE:RDY). Such

Sep 17, 2026, 10:00 AM ·PRNewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy’s Laboratories Limited - RDY

NEW YORK, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Dr. Reddy’s Laboratories Limited ("Dr. Reddy’s" or the "Company") (NYSE:RDY). Such

Sep 8, 2026, 5:42 PM ·Globe Newswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY

NEW YORK, Aug. 27, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Dr. Reddy's Laboratories Limited ("Dr. Reddy's" or the "Company") (NYSE:RDY). Such

Aug 27, 2026, 4:15 PM ·PRNewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy’s Laboratories Limited - RDY

NEW YORK, Aug. 25, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Dr. Reddy’s Laboratories Limited ("Dr. Reddy’s" or the "Company") (NYSE:RDY). Such investors

Aug 25, 2026, 6:25 PM ·Globe Newswire

Securities Fraud Investigation Into Dr. Reddy’s Laboratories (RDY) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm

Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Dr. Reddy’s Laboratories ("Dr. Reddy’s" or the

Aug 20, 2026, 11:00 AM ·Business Wire

Dr. Reddy’s Laboratories (RDY) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

Law Offices of Howard G. Smith announces an investigation on behalf of Dr. Reddy’s Laboratories ("Dr. Reddy’s" or the "Company") (NYSE: RDY) investors concerning the Company’s possible violations of

Aug 20, 2026, 9:00 AM ·Business Wire

Securities Fraud Investigation Into Dr. Reddy’s Laboratories (RDY) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz

The Law Offices of Frank R. Cruz announces an investigation of Dr. Reddy’s Laboratories ("Dr. Reddy’s" or the "Company") (NYSE: RDY) on behalf of investors concerning the Company’s possible violations

Aug 19, 2026, 6:17 PM ·Business Wire

RDY SHAREHOLDER ALERT: Dr. Reddy’s Laboratories Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations

The law firm of Kirby McInerney LLP reminds investors of its investigation on behalf of Dr. Reddy’s Laboratories ("Dr. Reddy’s" or the "Company") (NYSE:RDY) investors concerning the Company’s and/or

Aug 13, 2026, 8:00 PM ·Business Wire

DR. REDDY’S LABORATORIES INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud

NEW YORK, Aug. 05, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against Dr. Reddy’s Laboratories ("Dr. Reddy’s" or the "Company") (NYSE:RDY). The

Aug 5, 2026, 8:00 PM ·Globe Newswire

Dr. Reddy’s Announces the First-to-Market Launch of Sugammadex Injection 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials, a Generic Equivalent of Bridion®, in the United States

Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE:RDY, along with its subsidiaries together referred to as "Dr. Reddy’s") today announced the launch of Sugammadex Injection 200 mg/2 mL (100 mg/mL)

Aug 4, 2026, 1:39 AM ·Business Wire

Dr. Reddy's Laboratories (RDY) Securities Investigation Notice - Levi & Korsinsky

Investigation focuses on RDY losses after Dr. Reddy's disclosed a ₹2.4 billion provision tied to out-of-spec semaglutide batches and shares fell approximately 9%. NEW YORK, July 31, 2026 /PRNewswire/ -- On July 22,

Jul 31, 2026, 10:07 AM ·PRNewswire

Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving Dr. Reddy’s Laboratories (RDY)

NEW YORK, July 29, 2026 (GLOBE NEWSWIRE) -- Dr. Reddy’s Laboratories (NYSE:RDY) shares fell approximately 9% on July 22, 2026 after the Company disclosed a ₹2.4 billion provision tied to out-of-spec semaglutide

Jul 29, 2026, 10:07 AM ·Globe Newswire

RDY Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Dr. Reddy’s Laboratories (RDY)

The investigation focuses on RDY investor losses tied to Dr. Reddy’s FY27 margin guidance after the Company disclosed a ₹2.4 billion provision connected to out-of-spec semaglutide batches.RDY shareholders saw Dr.

Jul 28, 2026, 10:07 AM ·Business Wire

Dr. Reddy's Laboratories Limited RDY · News